ମେମାଣ୍ଟାଇନ

ମେମାଣ୍ଟାଇନ
Clinical data
Trade names	Axura, Ebixa, Namenda, others
AHFS/Drugs.com	monograph
MedlinePlus	a604006
data	EU EMA: yes; US DailyMed: Memantine;
Pregnancy; category	AU: B2 ; US: B (No risk in non-human studies) ; ;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Bioavailability	~100%
Metabolism	Liver (<10%)
Elimination half-life	60–100 hours
Excretion	Kidney
Identifiers
	IUPAC name 3,5-dimethyltricyclo[3.3.1.13,7]decan-1amine; or; 3,5-dimethyladamantan-1-amine;
ECHA InfoCard	100.217.937
Chemical and physical data
Formula	C12H21N
Molar mass	୧୭୯.୩୧ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES NC12CC3(CC(C1)(CC(C2)C3)C)C;
	InChI InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3 ; Key:BUGYDGFZZOZRHP-UHFFFAOYSA-N ;
(verify)

ମେମାଣ୍ଟାଇନ ହେଉଛି ଏକ ଔଷଧ ଯାହା ମଧ୍ୟମରୁ ଗମ୍ଭୀର ଆଲଜିମର ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ | ^[୨] ^[୩] ଏହା ଆସେଟିଲକୋଲିନଇଷ୍ଟରେଜ ଶ୍ରେଣୀର ଡୋନେପେଜିଲ ଅପେକ୍ଷା ଏହା କମ ପସନ୍ଦ କରାଯାଏ | ^[୪] ଉପକାରୀ ପ୍ରଭାବ ଦେଖାଗଲେ ଚିକିତ୍ସା ଜାରି ରଖିବା ଉଚିତ୍। ^[୪] ଏହା ପାଟିଏ ଦିଆଯାଏ | ^[୫]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡବିନ୍ଧା, କୋଷ୍ଠକାଠିନ୍ୟ, ନିଦ୍ରାଳୁ ଭାବ ଏବଂ ମୁଣ୍ଡ ବୁଲାଇବା ହୋଇପାରେ | ^[୨] ^[୩] ଗୁରୁତର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ରକ୍ତ ଜମାଟ ବାନ୍ଧିବା, ସାଇକୋସିସ୍ ଏବଂ ହୃଦ୍‌ପାତ ହୋଇପାରେ। ^[୪] ଏହା ଏନଏମଡିଏ ରିସେପ୍ଟର ଗୁଡ଼ିକୁ ଅବରୋଧ କରି ଏହା କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ବୋଲି ବିଶ୍ୱାସ କରାଯାଏ | ^[୫]

୨୦୦୩ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ମେମାଣ୍ଟାଇନ ଅନୁମୋଦିତ ହୋଇଥିଲା | ^[୨] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ | ଯୁକ୍ତରାଜ୍ୟରେ ଏକ ମାସର ଯୋଗାଣ ୨୦୧୯ ସୁଦ୍ଧା ଏନଏଚଏସର ମୂଲ୍ୟ ୧.୬୦ ପାଉଣ୍ଡ (GBP) ଅଟେ । ^[୩] ^[୪] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ହୋଲସେଲ ମୂଲ୍ୟ ପ୍ରାୟ ୫.୫୦ ଆମେରିକୀୟ ଡଲାର ଅଟେ। ^[୬] ୨୦୧୭ ମସିହାରେ ଏହା ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୧୪୯ତମ ସାଧାରଣ ପ୍ରେସକ୍ରିପସନ ଔଷଧ ଥିଲା, ଯେଉଁଥିରେ ଚାରି ଲକ୍ଷରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ ରହିଥିଲା | ^[୭] ^[୮]

ଆଧାର

↑ "International brands for memantine". Drugs.com. Retrieved 7 August 2017.
↑ ^୨.୦ ^୨.୧ ^୨.୨ "Memantine Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 3 March 2019.
↑ ^୩.୦ ^୩.୧ ^୩.୨ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 303–304. ISBN 9780857113382.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 303–304. ISBN 9780857113382.
↑ ^୫.୦ ^୫.୧ "Memantine Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 3 March 2019.
↑ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.
↑ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
↑ "Memantine Hydrochloride - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.

[brands-1] "International brands for memantine". Drugs.com. Retrieved 7 August 2017.

[AHFS2019-2] ୨.୦ ^୨.୧ ^୨.୨ "Memantine Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 3 March 2019.

[BNF76-3] ୩.୦ ^୩.୧ ^୩.୨ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 303–304. ISBN 9780857113382.

[autogen4-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 303–304. ISBN 9780857113382.

[autogen3-5] ୫.୦ ^୫.୧ "Memantine Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 3 March 2019.

[NADAC2019-6] "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.

[ref-7] "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.

[ref1-8] "Memantine Hydrochloride - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.

[୨]

[୩]

[୪]

[୫]

[୧]

[୬]

[୭]

[୮]

Clinical data


Trade names	Axura, Ebixa, Namenda, others^[୧]
AHFS/Drugs.com	monograph
MedlinePlus	a604006
data	EU EMA: yes US DailyMed: Memantine
Pregnancy category	AU: B2 US: B (No risk in non-human studies)
Routes of administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	~100%
Metabolism	Liver (<10%)
Elimination half-life	60–100 hours
Excretion	Kidney
Identifiers
IUPAC name 3,5-dimethyltricyclo[3.3.1.1^3,7]decan-1amine or 3,5-dimethyladamantan-1-amine
ECHA InfoCard	100.217.937
Chemical and physical data
Formula	C₁₂H₂₁N
Molar mass	୧୭୯.୩୧ g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES NC12CC3(CC(C1)(CC(C2)C3)C)C
InChI InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3^Y Key:BUGYDGFZZOZRHP-UHFFFAOYSA-N^Y
(verify)